

**STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

Docket No.
15004Z

In Re Application Of: **Alan P. Kozlikowski, et al.**

Application No.
09/246,307

Filing Date
2/8/1999

Examiner
A. Gupta

Customer No.
23389

Group Art Unit
1653

Confirmation No.
6016

Invention: **CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS
NEURODEGENERATIVE DISORDERS**

COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.


Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.


Signature

**Mark J. Cohen
Registration No. 32,211
Scully, Scott, Murphy & Presser
400 Garden City, Suite 300
Garden City, NY 11530
(516) 742-4343**


Dated: **February 15, 2005**

Certificate of Mailing by First Class Mail

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

2/15/2005

(Date)


Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Correspondence

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alan P. Kozikowski, et al. **Examiner:** A. Gupta
Serial No.: 09/246,307 **Art Unit:** 1653
Filed: February 8, 1999 **Docket:** 15004Z
For: CYCLIC DIPEPTIDES AND
AZETIDINONE COMPOUNDS AND
THEIR USE IN TREATING CNS INJURY
AND NEURODEGENERATIVE DISORDERS **Dated:** February 15, 2005



Confirmation No.: 6016

Mailstop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Massimo Falorni, et al. "Chiral Ligands Containing Heteroatoms. 11.¹ Optically Active 2-Hydroxymethyl Piperazines as Catalysts in the Enantioselective Addition of Diethylzinc to Benzaldehyde", Tetrahedron Asymmetry, Vol. 4, No. 11, pp. 2389-2398, (1993); and
2. Gamini S. Jayatilake, et al., "Metabolites from an Antarctic Sponge-Associated Bacterium, *Pseudomonas Aeruginosa*", J. Nat. Prod., Vol. 59, pp. 293-296, (1996).

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 15, 2005


Mark J. Cohen


The references were cited in a Supplementary Partial Search Report dated January 7, 2005, received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Supplementary Partial Search Report. The relevance of the above-identified references has been described in the Supplementary Partial Search Report.

This Information Disclosure Statement is accompanied by a Statement under 37 C.F.R. §1.97(e) after the issuance of an Official Action, but before the issuance of a Final Rejection or Notice of Allowance. Inasmuch as these references were cited in a Search Report that issued within 3-months of the filing hereof and inasmuch as the Information Disclosure Statement is accompanied by a Statement in accordance with 37 C.F.R. § 1.97(e), no fee is required.

Respectfully submitted,

Mark J. Cohen.
Registration No. 32,211

Scully, Scott, Murphy & Presser
400 Garden City Plaza, Suite 300
Garden City, New York 11530
Telephone: (516) 742-4343

MJC:ng

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Atty. Docket No. (Optional) 15004Z	Application Number 09/246,307				
		Applicant(s) Alan P. Kozikowski, et al.					
		Filing Date February 8, 1999	Group Art Unit 1653				
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		Massimo Falorni, et al. "Chiral Ligands Containing Heteroatoms. 11. ¹ Optically Active 2-Hydroxymethyl Piperazines as Catalysts in the Enantioselective Addition of Diethylzinc to Benzaldehyde", <u>Tetrahedron Asymmetry</u> , Vol. 4, No. 11, pp. 2389-2398, (1993)					
		Gamini S. Jayatilake, et al., "Metabolites from an Antarctic Sponge-Associated Bacterium, <i>Pseudomonas Aeruginosa</i> ", <u>J. Nat. Prod.</u> , Vol. 59, pp. 293-296, (1996)					
EXAMINER		DATE CONSIDERED					
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							